FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004067129> ?p ?o ?g. }

• W3004067129 endingPage "2051" @default.
• W3004067129 startingPage "2039" @default.
• W3004067129 abstract "Abstract Treatment with PEGylated interferon‐alpha2 (IFN) of patients with essential thrombocythemia and polycythemia vera induces major molecular remissions with a reduction in the JAK2 V617F allele burden to undetectable levels in a subset of patients. A favorable response to IFN has been argued to depend upon the tumor burden, implying that institution of treatment with IFN should be as early as possible after the diagnosis. However, evidence for this statement is not available. We present a thorough analysis of unique serial JAK2 V617F measurements in 66 IFN‐treated patients and in 6 untreated patients. Without IFN treatment, the JAK2 V617F allele burden increased exponentially with a period of doubling of 1.4 year. During monotherapy with IFN, the JAK2 V617F allele burden decreased mono‐ or bi‐exponentially for 33 responders of which 28 patients satisfied both descriptions. Bi‐exponential description improved the fits in 19 cases being associated with late JAK2 V617F responses. The decay of the JAK2 V617F allele burden during IFN treatment was estimated to have half‐lives of 1.6 year for the monoexponential response and 1.0 year in the long term for the bi‐exponential response. In conclusion, through data‐driven analysis of the JAK2 V617F allele burden, we provide novel information regarding the JAK2 V617F kinetics during IFN‐treatment, arguing for early intervention." @default.
• W3004067129 created "2020-02-07" @default.
• W3004067129 creator A5011870816 @default.
• W3004067129 creator A5022857754 @default.
• W3004067129 creator A5027085121 @default.
• W3004067129 creator A5032458008 @default.
• W3004067129 creator A5040766343 @default.
• W3004067129 creator A5053726532 @default.
• W3004067129 creator A5055349836 @default.
• W3004067129 creator A5056736397 @default.
• W3004067129 creator A5061912632 @default.
• W3004067129 creator A5063997919 @default.
• W3004067129 creator A5069287220 @default.
• W3004067129 creator A5074023164 @default.
• W3004067129 creator A5075557171 @default.
• W3004067129 creator A5091728803 @default.
• W3004067129 date "2020-01-28" @default.
• W3004067129 modified "2023-10-16" @default.
• W3004067129 title "Data‐driven analysis of <i>JAK2</i> V617F kinetics during interferon‐alpha2 treatment of patients with polycythemia vera and related neoplasms" @default.
• W3004067129 cites W1547986283 @default.
• W3004067129 cites W1793206271 @default.
• W3004067129 cites W1852968885 @default.
• W3004067129 cites W1884746267 @default.
• W3004067129 cites W1966230381 @default.
• W3004067129 cites W1968468753 @default.
• W3004067129 cites W1970553871 @default.
• W3004067129 cites W1980568348 @default.
• W3004067129 cites W1981240373 @default.
• W3004067129 cites W1983892731 @default.
• W3004067129 cites W1993072636 @default.
• W3004067129 cites W1995162107 @default.
• W3004067129 cites W1997264913 @default.
• W3004067129 cites W1999025699 @default.
• W3004067129 cites W2010075352 @default.
• W3004067129 cites W2014600438 @default.
• W3004067129 cites W2022939548 @default.
• W3004067129 cites W2025848587 @default.
• W3004067129 cites W2027613124 @default.
• W3004067129 cites W2029466025 @default.
• W3004067129 cites W2030716854 @default.
• W3004067129 cites W2045399297 @default.
• W3004067129 cites W2048488970 @default.
• W3004067129 cites W2049145190 @default.
• W3004067129 cites W2057360098 @default.
• W3004067129 cites W2057650885 @default.
• W3004067129 cites W2064690570 @default.
• W3004067129 cites W2066465348 @default.
• W3004067129 cites W2069133834 @default.
• W3004067129 cites W2073660297 @default.
• W3004067129 cites W2089474120 @default.
• W3004067129 cites W2093290834 @default.
• W3004067129 cites W2094487700 @default.
• W3004067129 cites W2097692898 @default.
• W3004067129 cites W2099262599 @default.
• W3004067129 cites W2099264304 @default.
• W3004067129 cites W2110190127 @default.
• W3004067129 cites W2110982533 @default.
• W3004067129 cites W2116813423 @default.
• W3004067129 cites W2125641817 @default.
• W3004067129 cites W2135367830 @default.
• W3004067129 cites W2138709799 @default.
• W3004067129 cites W2144664431 @default.
• W3004067129 cites W2146415428 @default.
• W3004067129 cites W2147349522 @default.
• W3004067129 cites W2147370660 @default.
• W3004067129 cites W2149373649 @default.
• W3004067129 cites W2153170459 @default.
• W3004067129 cites W2157114147 @default.
• W3004067129 cites W2157694607 @default.
• W3004067129 cites W2165542165 @default.
• W3004067129 cites W2170562221 @default.
• W3004067129 cites W2171775508 @default.
• W3004067129 cites W2211640958 @default.
• W3004067129 cites W2218840816 @default.
• W3004067129 cites W2292715199 @default.
• W3004067129 cites W2537259361 @default.
• W3004067129 cites W2570736466 @default.
• W3004067129 cites W2576709950 @default.
• W3004067129 cites W2594084141 @default.
• W3004067129 cites W2606042248 @default.
• W3004067129 cites W2757102439 @default.
• W3004067129 cites W2767250221 @default.
• W3004067129 cites W2784395700 @default.
• W3004067129 cites W2793205496 @default.
• W3004067129 cites W2889734305 @default.
• W3004067129 cites W2891873864 @default.
• W3004067129 cites W2950331762 @default.
• W3004067129 doi "https://doi.org/10.1002/cam4.2741" @default.
• W3004067129 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7064092" @default.
• W3004067129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31991066" @default.
• W3004067129 hasPublicationYear "2020" @default.
• W3004067129 type Work @default.
• W3004067129 sameAs 3004067129 @default.
• W3004067129 citedByCount "19" @default.
• W3004067129 countsByYear W30040671292020 @default.
• W3004067129 countsByYear W30040671292021 @default.
• W3004067129 countsByYear W30040671292022 @default.
• W3004067129 countsByYear W30040671292023 @default.

• next